View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 14, 2021

NeuroBo to continue Phase II/III Covid drug trial without modifications

The DMC reviewed safety results from 36 Covid-19 patients treated with the company’s oral niclosamide formulation ANA001.

NeuroBo Pharmaceuticals has obtained a recommendation from the independent Data Monitoring Committee (DMC) to continue the Phase II/III clinical trial of its lead drug candidate, ANA001, for treating Covid-19 without any changes.

The move comes after the committee reviewed safety data from 36 subjects who received treatment with ANA001 in the trial.

ANA001 is a proprietary oral formulation of niclosamide, which features antiviral and anti-inflammatory properties.

The two-part multicentre, placebo-controlled double-blind Phase II/III trial is analysing the safety, tolerability and efficacy of ANA001.

Being carried out in the US, both phases of the trial will have subjects suffering with moderate to severe Covid-19 who are in hospital but do not need ventilators.

These subjects will be given ANA001 plus standard-of-care therapy for seven days.

The Phase II trial anticipates recruiting 60 subjects with a primary goal to analyse the safety and tolerability of the drug.

Efficacy measurements such as median time to hospital discharge and pharmacokinetics will be included as secondary goals.

The Phase III segment will enrol several hundred subjects.

Median time to hospital discharge, safety and tolerability will be the primary goals of this phase, while clinical improvement and the requirements and time for rescue treatment will be the secondary goals.

NeuroBo president and CEO Richard Kang said: “The DMC’s recommendation to continue enrolment of the Phase II/III clinical trial, without modification, is an important milestone for our lead drug candidate, ANA001, as a potential treatment for Covid-19.

“We expect to complete the Phase II portion of the trial in the fourth quarter of this year and to achieve a number of value-creating milestones with this programme in the coming months, including initiation of the Phase III of trial.”

In a separate development, TC BioPharm has commenced a Phase I/II trial of its allogeneic gamma-delta T cell product, ImmuniStim, in subjects with Covid-19 in the UK.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy